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Editorial on the Research Topic
Renal Hypertension at the Crossroads: Theoretical, Experimental and Clinical Aspects
Since Goldblatt’s seminal experiment in Goldblatt et al. (1), renal hypertension has increasingly
been recognized as an important cause of secondary hypertension and chronic kidney disease,
the latter by virtue of renal ischemia. Followed later by important work, the scientific community
recognized that renal artery occlusion does not only increase systemic blood pressure by decreased
transstenotic blood flow but by an array of multiple systemic or local mechanisms, which all
contribute to high blood pressure and hypertension-related injury. The contributions made in this
Frontiers Research Topic are significant because they add to considerations that have been given
to the kidney in hypertension and relative to its role in vascular function. The control of renal and
cardiovascular hemodynamics and renal function in hypertension was elegantly discussed (Sata
et al.). Resistant hypertension is generally defined as uncontrolled blood pressure (>140/90mm
Hg) after treatment with three or more antihypertensives. Salt sensitivity was studied in resistant
hypertension and renal denervation using an in vitro erythrocyte salt sedimentation assay (Vonend
et al.). Alamandine and its receptor were identified as novel protective contributors to the
renin-angiotensin system (Schleifenbaum). A novel hierarchical statistical method and genetically
encoded calcium indicators (GECIs) have been implemented in experimental hypertension
(Tsvetkov et al.; Zhong and Schleifenbaum). Caveolae associated signal transduction pathways
were identified in vasculature to play important pathophysiological role in hypertension (Lian
et al.). Together, the authors explicitly place findings that can be taken advantage of in creating
new therapies and experimental models for cardiovascular diseases that continue to challenge our
community. These include resistant hypertension, renal artery interventions, therapeutic targeting
of endothelial cells and perivascular adipose tissue, and salt consumption in health and disease to
name a few. We are grateful to our contributors for sharing their important work.
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